Arvinas, Inc. (ARVN)

Over the past six months, Arvinas' stock has been impacted by several events. The FDA approved VEPPANU (Vepdegestrant) for ESR1-mutated, ER+/HER2- advanced breast cancer, leading to a stock increase. The company reported a significant miss on its Q4 2025 earnings and revenue, resulting in a stock decline. Positive Phase 1 data for ARV-102 was announced. Analyst ratings have been mixed, with some downgrades and some upgrades. Arvinas announced a plan to cut 15% of its staff.

There is no specific information indicating demand seasonality for Arvinas, Inc.'s products and services. Demand for their future commercialized products would likely be driven by medical need and regulatory approvals rather than seasonal patterns.

Arvinas, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies that degrade disease-causing proteins. Their core technology is the PROTAC protein degrader platform, designed to selectively degrade and remove pathogenic proteins. The company's clinical development program includes product candidates targeting oncology and neurology-related diseases, such as Vepdegestrant, ARV-102, ARV-393, ARV-806, ARV-027 and ARV-766.

Arvinas, Inc. is headquartered in New Haven, Connecticut, United States, which serves as the company's main operational hub. The company has employees across five continents, including North America, Europe, and Asia.

Arvinas' brand reputation has been influenced by its clinical progress and financial performance. The FDA approval of VEPPANU enhanced the company's scientific credibility. However, a significant Q4 2025 earnings and revenue miss and a workforce reduction have posed challenges. Analyst sentiment is mixed, reflecting the balance between the promise of its innovative PROTAC platform and financial challenges.

Arvinas, Inc. is primarily owned by institutional shareholders, with 211 institutional owners holding a total of 54,738,237 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, D. E. Shaw & Co., Inc., Pfizer Inc, Point72 Asset Management, L.P., State Street Corp, Armistice Capital, Llc, Geode Capital Management, Llc, New Leaf Venture Partners, L.L.C. and Qube Research & Technologies Ltd. Timothy M. Shannon is the largest individual shareholder, owning 6.22 million shares, representing 9.73% of the company. Other notable individual owners include Canaan IX LP, Ra Capital Management LP, and Craig Martin Crews.